Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | TPO | P07202 | 1/20 | 0.42 |
| ▸ | EPX | P11678 | 1/20 | 0.42 |
| ▸ | LPO | P22079 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736374 | 0.85 | ERBB2 (0.46) | ERBB2LMNAMEN1KMT2AEGFR | |
| SCHEMBL20172428 | 0.82 | MPO (0.46) | MPOTPOEPXLPOERBB2 | |
| SCHEMBL159190 | 0.79 | MPO (0.51) | MPOTPOEPXLPOERBB2 | |
| SCHEMBL4799461 | 0.79 | MPO (0.44) | MPOTPOEPXLPOERBB2 | |
| SCHEMBL23922346 | 0.79 | FFAR1 (0.56) | FFAR1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12851586 | 0.77 | CYP2C19 (0.46) | MPOTPOEPXLPOFFAR1 | |
| SCHEMBL12855074 | 0.77 | ACACB (0.44) | MPOTPOEPXLPOACACB | |
| SCHEMBL13026533 | 0.77 | FFAR1 (0.43) | FFAR1LMNAMAPTSMN1; SMN2NPBWR1 | |
| SCHEMBL875619 | 0.76 | TTR (0.46) | MPOTPOEPXLPOFFAR1 | |
| SCHEMBL875575 | 0.76 | TTR (0.45) | MPOTPOEPXLPOLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | MPO 4589/4885TPO 3610/4885EPX 856/4885 |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | MPO 4866/4885TPO 4683/4885EPX 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.